AbbVie (ABBV) Tops Q2 EPS by 3c, Updates Guidance

July 30, 2021 7:45 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

AbbVie (NYSE: ABBV) reported Q2 EPS of $3.11, $0.03 better than the analyst estimate of $3.08. Revenue for the quarter came in at $13.96 billion versus the consensus estimate of $13.61 billion.


AbbVie sees FY2021 EPS of $12.52-$12.62, versus the consensus of $12.60.

  • AbbVie is updating its GAAP diluted EPS guidance for the full-year 2021 from $7.27 to $7.47 to $6.04 to $6.14. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.37 to $12.57 to $12.52 to $12.62. The company's 2021 adjusted diluted EPS guidance excludes $6.48 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities